STAT August 11, 2024
The Food and Drug Administration’s decision not to approve Lykos Therapeutics’ application for MDMA (a psychedelic drug known on the street as Ecstasy or molly) plus therapy for post-traumatic stress disorder comes as no surprise, given an advisory panel’s “no” vote on the application in June. But if lessons from reproductive health are any signal, I believe there is a future for psychedelics in health care.
As executive director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, my work includes legal, ethical, and policy analysis surrounding psychedelic medicine. As part of our growing Project on Psychedelics Law and Regulation, we’ve hosted two major convenings on this topic this summer alone. Most participants seemed...
Today's Sponsors
Today's Sponsor